Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck
Biotech
2 pharmas turn Scrooge, returning biotechs' unwanted gifts
The hand-back marks today's second pharma walk-away after Boehringer Ingelheim turned down its chance to license Nxera's schizophrenia candidate.
Gabrielle Masson
Dec 19, 2025 10:44am
Merck's PCSK9 drug mounts injectable-like cholesterol reductions
Nov 10, 2025 10:59am
Merck opts in on Evaxian's preclinical vaccine candidate
Sep 25, 2025 7:00am
Merck scraps £1B project, along with all R&D operations in UK
Sep 10, 2025 3:40pm
Fierce Pharma
Merck unveils $3B cost-cutting plan
Jul 29, 2025 8:15am
Merck wades deeper into HIV PrEP waters with pair of trials
Jul 14, 2025 1:12pm
